Latest:
Well-Differentiated Systemic Mastocytosis vs Chronic Mast Cell Leukemia
The panel of experts discuss the clinical differences between well-differentiated systemic mastocytosis and chronic mast cell leukemia.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Ken Culver, MD
Ken Culver, MD, is the director of Research and Clinical Affairs at ALK Positive Inc
Latest:
How a Career of Hearing and Amplifying Patient Voices Has Reached the Pinnacle of Patient Advocacy: With D. Ross Camidge, MD, PhD; and Ken Culver, MD
Drs Camidge and Culver discuss the highlights of Dr Culver's career, shaped by clinical practice, research, leadership, and patient advocacy.
Andrew John Armstrong, MD, MSc
Latest:
Overcoming Barriers to Cabazitaxel and Optimizing Sequencing
Evidence-based approaches to cabazitaxel use in mCRPC, addressing treatment sequencing after prior therapies, real-world underutilization trends, patient counseling on benefits and risks, and FDA guidance on dosing strategies to optimize outcomes while managing toxicity.
Ryan M. Khan, MD, MHS, FACOG
Ryan Matthew Kahn, M.D., MHS, FACOG, is a gynecologic oncologist at Baptist Health Miami Cancer Institute.
Latest:
Dr Kahn on Recognizing Surgical Limitations in Advanced Ovarian Cancer During Ovarian Cancer Awareness Month
Ryan Matthew Kahn, MD, MHS, FACOG, discusses the importance of recognizing surgical limitations in the treatment of patients with advanced ovarian cancer.
Marc R. Matrana, MD
Marc R. Matrana, MD, is a medical oncologist and director of Genitourinary Medical Oncology Research at Ochsner MD Anderson Cancer Center, as well as a professor of internal medicine at The University of Queensland Medical School – Ochsner Health.
Latest:
Dr Matrana on the Persisting Need For Validated Biomarkers to Guide Treatment Selection in RCC
Marc R. Matrana, MD, discusses the ongoing need for validated biomarkers to guide treatment selection in renal cell carcinoma.
Jeanny B. Aragon-Ching, MD, FACP
Latest:
Considerations When Treating Patients With Metastatic Renal Cell Carcinoma
Similar to first-line therapy choices, particular treatment factors, including type
and duration of response to prior therapy, pace of disease progression, and toxicities associated with first-line treatment, are all practical considerations that help guide therapy selection in metastatic renal cell carcinoma.
O’Neal Comprehensive Cancer Center at the University of Alabama at Birmingham
Latest:
Bredel Findings Address Understanding of Diffuse Gliomas
A groundbreaking discovery by Markus Bredel, MD, PhD, and colleagues not only marks a significant milestone in our understanding of diffuse gliomas but also paves the way for improved predictions of disease outcomes and the development of targeted treatment approaches.
Claire Roddie, MD, PhD
Latest:
Obecabtagene Autoleucel (obe-cel, AUTO1) for Relapsed/Refractory Adult B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL): Pooled Analysis of the Ongoing FELIX Phase Ib/II Study
Claire Roddie, MD, PhD, presents data from the pooled analysis of the ongoing FELIX phase Ib/II study investigating obecabtagene autoleucel in patients with relapsed/refractory adult B-cell acute lymphoblastic leukemia.
Bogdana Schmidt
Bogdana Schmidt, MD, MPH, is an assistant professor in the Division of Urology at the University of Utah Huntsman Cancer Institute in Salt Lake City.
Latest:
Dr Schmidt on the Role of Minimally Invasive and Robotic Modalities in Bladder Cancer
Bogdana Schmidt, MD, MPH, discusses the role of minimally invasive and robotic strategies for the treatment of patients with bladder cancer.
Jessica C. Hassel, MD
Jessica C. Hassel, MD is a dermato-oncologist working at the University Hospital in Heidelberg, Germany.
Latest:
Dr Hassel on the Rationale for Combining IO102-IO103 with Pembrolizumab in Treatment-Naive Advanced Melanoma
Jessica C. Hassel, MD, discusses rationale for combining IO102-IO103 with pembrolizumab in patients with treatment-naive advanced melanoma.
Joachim G. J. V. Aerts, MD, PhD
Latest:
Dr Aerts on the Rationale for the DENIM Trial in Mesothelioma
Joachim G. J. V. Aerts, MD, PhD, discusses the rationale for conducting the phase 3 DENIM trial in patients with mesothelioma, highlighting the importance of focusing investigational efforts onto the dendritic cells.
UPMC Hillman Cancer Center
Latest:
Illumination of Immune Checkpoint LAG3 ‘Black Box’ Could Yield New Cancer and Autoimmune Therapies
A new study pinpoints how LAG3 modulates T cell activity, providing important insights for development of other LAG3-blocking therapies for cancer and autoimmune disorders.